Opportunity Information: Apply for PAR 22 057
The NIH funding opportunity PAR 22-057, titled "Emergency Awards: HEAL Initiative: Translational Science Career Enhancement Awards for Early and Mid-career Investigators (K18 Clinical Trials Not Allowed)," is designed to help early and mid-career researchers broaden their capabilities in translational science, specifically around the development of therapeutics such as drugs, biologics, and medical devices. The program sits within the HEAL (Helping to End Addiction Long-term) Initiative and is motivated by the urgent public health need to accelerate new and better treatments for pain, opioid use disorder, addiction more broadly, and overdose. The central idea is to strengthen the workforce of scientists who can move discoveries from basic research settings into practical interventions that improve individual and population health.
This FOA emphasizes translational science as more than simply applying laboratory findings to humans. It describes translation as the full pathway of turning observations from the lab, clinic, and community into real-world interventions, ranging from diagnostics and therapeutics to procedures and behavioral changes. In that framing, translational science is the discipline that studies how each step of the translational pipeline works, including both scientific and operational principles. The opportunity is aimed at investigators who already have solid domain expertise in a particular field but want to gain a broader, more integrated understanding of what it takes to shepherd an idea through the key stages of therapeutic development.
A major rationale for the award is that traditional academic training often produces deep specialization, which is valuable, but does not always provide practical exposure to the multiple specialized domains involved in therapeutic product development. The FOA specifically highlights the complexity of the expertise needed to assemble regulatory and development packages such as an Investigational New Drug (IND) application for drugs/biologics, an Investigational Device Exemption (IDE) for devices, or a New Drug Application (NDA) for marketing approval. Because these processes require familiarity with a wide range of areas (for example, preclinical development strategy, manufacturing and quality considerations, regulatory science, and other operational steps), the FOA positions this K18 as a way for eligible investigators to obtain targeted, participatory training that would otherwise be difficult to access within a conventional academic career path.
The target applicant pool is described as early and mid-career investigators, with examples spanning postdoctoral fellows/associates through associate professors. While the FOA is a career enhancement mechanism, it is not structured to support independent clinical trials, as indicated by the "Clinical Trials Not Allowed" designation. In practice, that means the supported activities are meant to focus on skill and knowledge acquisition and career development in translational science and therapeutic development rather than running a clinical trial as part of the award.
Eligible applicant organizations are broad and include many types of U.S.-based institutions and entities, such as public and private institutions of higher education, nonprofit organizations (with or without 501(c)(3) status), for-profit organizations (other than small businesses) and small businesses, as well as various units of government (state, county, city/township, special districts), independent school districts, and public housing authorities/Indian housing authorities. The FOA also explicitly calls out additional eligible categories that NIH often highlights to encourage wide participation, including Alaska Native and Native Hawaiian Serving Institutions, AANAPISIs, Hispanic-serving Institutions, Historically Black Colleges and Universities (HBCUs), Tribally Controlled Colleges and Universities (TCCUs), faith-based or community-based organizations, regional organizations, U.S. territories or possessions, eligible federal agencies, and Indian/Native American tribal governments and tribal organizations (including those other than federally recognized, as specified).
At the same time, there are clear geographic and organizational restrictions related to foreign involvement. Non-domestic (non-U.S.) entities and non-domestic foreign institutions are not eligible to apply as applicant organizations, and non-domestic components of U.S. organizations are also not eligible. However, the FOA allows "foreign components" as defined in the NIH Grants Policy Statement, meaning a U.S. applicant organization may include certain foreign elements within the project if they meet NIH policy definitions and requirements. This structure preserves the award as primarily U.S.-anchored while still permitting justified international collaboration components under NIH rules.
From the listing information provided, this is a discretionary grant opportunity under the NIH, with activity and subject areas tied to education and health. The FOA is associated with multiple CFDA numbers (93.121, 93.213, 93.273, 93.279, 93.313, 93.350, 93.398, 93.846, 93.853, 93.866), reflecting its alignment with several NIH institutes, centers, and program authorities connected to translational science and the HEAL Initiative. The original closing date shown is January 22, 2022, and the record creation date is January 6, 2022. The award ceiling and expected number of awards are not specified in the provided source data, suggesting applicants would need to consult the full FOA text and NIH guidance for budget limits, project period details, and any cohort or funding level expectations.Apply for PAR 22 057
- The National Institutes of Health in the education, health sector is offering a public funding opportunity titled "Emergency Awards: HEAL Initiative: Translational Science Career Enhancement Awards for Early and Mid-career Investigators (K18 Clinical Trials Not Allowed)" and is now available to receive applicants.
- Interested and eligible applicants and submit their applications by referencing the CFDA number(s): 93.121, 93.213, 93.273, 93.279, 93.313, 93.350, 93.398, 93.846, 93.853, 93.866.
- This funding opportunity was created on 2022-01-06.
- Applicants must submit their applications by 2022-01-22. (Agency may still review applications by suitable applicants for the remaining/unused allocated funding in 2026.)
- Eligible applicants include: State governments, County governments, City or township governments, Special district governments, Independent school districts, Public and State controlled institutions of higher education, Native American tribal governments (Federally recognized), Public housing authorities/Indian housing authorities, Native American tribal organizations (other than Federally recognized tribal governments), Nonprofits having a 501 (c) (3) status with the IRS, other than institutions of higher education, Nonprofits that do not have a 501 (c) (3) status with the IRS, other than institutions of higher education, Private institutions of higher education, For-profit organizations other than small businesses, Small businesses, Others.
[Watch] Creating a grant proposal using the step-by-step wizard inside the applicant portal:
Frequently Asked Questions (FAQs)
1) What is NIH PAR 22-057?
PAR 22-057 is an NIH funding opportunity titled "Emergency Awards: HEAL Initiative: Translational Science Career Enhancement Awards for Early and Mid-career Investigators (K18 Clinical Trials Not Allowed)." It supports career enhancement activities that help investigators expand their capabilities in translational science focused on therapeutic development.
2) What is the main goal of this funding opportunity?
The goal is to strengthen the workforce of scientists who can move discoveries from basic research settings into practical interventions that improve individual and population health, with an emphasis on accelerating new and better treatments related to pain, opioid use disorder, addiction, and overdose.
3) How does this FOA define "translational science"?
Translational science is framed as the discipline that studies how the full translational pipeline works, including scientific and operational principles. Translation is described as the full pathway of turning observations from the lab, clinic, and community into real-world interventions, including diagnostics, therapeutics, procedures, and behavioral changes.
4) What types of therapeutics are emphasized?
The opportunity specifically highlights the development of therapeutics such as drugs, biologics, and medical devices.
5) How is this FOA connected to the HEAL Initiative?
This program sits within the NIH HEAL (Helping to End Addiction Long-term) Initiative and is motivated by the urgent public health need to speed up development of treatments related to pain, opioid use disorder, addiction more broadly, and overdose.
6) Who is this award intended for?
It is aimed at early and mid-career investigators. Examples mentioned include individuals ranging from postdoctoral fellows/associates through associate professors.
7) Is this a training grant or a research project grant?
Based on the information provided, it is a career enhancement mechanism (K18) designed for skill and knowledge acquisition and professional development in translational science and therapeutic development, rather than a mechanism primarily intended to support running a research project like an independent clinical trial.
8) Why does NIH describe a need for this type of award?
The FOA notes that traditional academic training often produces deep specialization but may not provide practical exposure to the many specialized domains required for therapeutic product development. This award is positioned to provide targeted, participatory training that can be difficult to access through a conventional academic career path.
9) What kinds of skills or areas of exposure does the FOA highlight?
The FOA highlights the complexity involved in developing regulatory and development packages such as an IND (for drugs/biologics), an IDE (for devices), or an NDA (for marketing approval). It points to the need for familiarity with areas such as preclinical development strategy, manufacturing and quality considerations, regulatory science, and other operational steps.
10) Are clinical trials allowed under this opportunity?
No. The title explicitly states "K18 Clinical Trials Not Allowed," and the description indicates supported activities are meant to focus on skill and knowledge acquisition and career development rather than running a clinical trial as part of the award.
11) Can an applicant include clinical trial-related work at all?
The provided information only states that independent clinical trials are not supported under this FOA. It does not describe any exceptions or allowable clinical trial-related activities beyond that statement.
12) What types of organizations are eligible to apply?
Eligible applicant organizations are broad and include U.S.-based public and private institutions of higher education, nonprofit organizations (with or without 501(c)(3) status), for-profit organizations (other than small businesses) and small businesses, and multiple types of government entities (state, county, city/township, special districts), independent school districts, and public housing authorities/Indian housing authorities.
13) Are minority-serving institutions and community-based organizations included as eligible applicants?
Yes. The FOA explicitly calls out Alaska Native and Native Hawaiian Serving Institutions, AANAPISIs, Hispanic-serving Institutions, Historically Black Colleges and Universities (HBCUs), Tribally Controlled Colleges and Universities (TCCUs), as well as faith-based or community-based organizations and regional organizations.
14) Are U.S. territories included?
Yes. The eligibility list includes U.S. territories or possessions.
15) Are tribal governments and tribal organizations eligible?
Yes. The FOA includes Indian/Native American tribal governments and tribal organizations, including categories specified as eligible even if other than federally recognized (as stated in the provided description).
16) Can a non-U.S. (foreign) organization apply as the main applicant?
No. Non-domestic (non-U.S.) entities and non-domestic foreign institutions are not eligible to apply as applicant organizations.
17) Can a U.S. organization with a non-U.S. component apply?
Non-domestic components of U.S. organizations are not eligible. However, the FOA allows "foreign components" as defined in the NIH Grants Policy Statement, meaning a U.S. applicant may include certain foreign elements within the project if they meet NIH policy definitions and requirements.
18) What does it mean that "foreign components" may be allowed?
It means the award is primarily U.S.-anchored, but a U.S. applicant organization may include justified international collaboration elements that meet NIH definitions and requirements for a foreign component under NIH policy.
19) What subject areas does this opportunity fall under?
From the listing information provided, the opportunity is tied to education and health, and it aligns with translational science and the HEAL Initiative.
20) Is this considered a discretionary grant opportunity?
Yes. The listing information indicates it is a discretionary grant opportunity under NIH.
21) Are there CFDA numbers associated with this FOA?
Yes. The FOA is associated with multiple CFDA numbers: 93.121, 93.213, 93.273, 93.279, 93.313, 93.350, 93.398, 93.846, 93.853, and 93.866.
22) Are the award ceiling or the expected number of awards provided?
No. The provided source data does not specify an award ceiling or an expected number of awards. The description suggests applicants would need to consult the full FOA text and NIH guidance for budget limits, project period details, and any cohort or funding level expectations.
23) What is the closing date listed for this opportunity?
The original closing date shown is January 22, 2022.
24) When was this opportunity record created?
The record creation date shown is January 6, 2022.
25) What is the central workforce issue this FOA is trying to address?
The FOA is responding to the gap between deep academic specialization and the cross-domain, practical expertise needed to shepherd a therapeutic idea through development stages, including regulatory and operational milestones. It aims to expand investigators' integrated understanding of therapeutic development.
Browse more opportunities from the same category: Education, Health
Next opportunity: Thailand - U.S. Embassy Julia Taft Fund for FY2022
Previous opportunity: HEAL Initiative: Harm Reduction Policies, Practices, and Modes of Delivery for Persons with Substance Use Disorders (R01 Clinical Trial Optional)
Applicant Portal:
Are you interested in learning about about how to apply for this government funding opportunity? You can create a free applicant account and receive instant access to our applicant portal that many business owners like you have benefited from.
Apply for PAR 22 057
Applicants also applied for:
Applicants who have applied for this opportunity (PAR 22 057) also looked into and applied for these:
| Funding Opportunity |
|---|
| Accelerating the Pace of Drug Abuse Research Using Existing Data (R01 Clinical Trial Optional) Apply for RFA DA 22 037 Funding Number: RFA DA 22 037 Agency: National Institutes of Health Category: Education, Health Funding Amount: Case Dependent |
| Health Care Models for Persons with Multiple Chronic Conditions from Populations that Experience Health Disparities: Advancing Health Care towards Health Equity (R01 - Clinical Trials Optional) Apply for PAR 22 092 Funding Number: PAR 22 092 Agency: National Institutes of Health Category: Education, Health Funding Amount: Case Dependent |
| Accelerating the Pace of Drug Abuse Research Using Existing Data (R21 Clinical Trial Optional) Apply for RFA DA 22 038 Funding Number: RFA DA 22 038 Agency: National Institutes of Health Category: Education, Health Funding Amount: Case Dependent |
| Exploratory/Developmental Bioengineering Research Grants (EBRG) (R21 Clinical Trial Optional) Apply for PAR 22 091 Funding Number: PAR 22 091 Agency: National Institutes of Health Category: Education, Health Funding Amount: $275,000 |
| Exploratory/Developmental Bioengineering Research Grants (EBRG) (R21 Clinical Trial Not Allowed) Apply for PAR 22 090 Funding Number: PAR 22 090 Agency: National Institutes of Health Category: Education, Health Funding Amount: $275,000 |
| Epidemiologic Research on Emerging Risk Factors and Liver Cancer Susceptibility (R21 Clinical Trial Not Allowed) Apply for PAR 22 084 Funding Number: PAR 22 084 Agency: National Institutes of Health Category: Education, Health Funding Amount: Case Dependent |
| Emergency Awards: HEAL Initiative-Early-Stage Discovery of New Pain and Opioid Use Disorder Targets Within the Understudied Druggable Proteome (R21 Clinical Trial Not Allowed) Apply for RFA TR 22 011 Funding Number: RFA TR 22 011 Agency: National Institutes of Health Category: Education, Health Funding Amount: $275,000 |
| Stimulating Access to Research in Residency (StARR) (R38) Apply for RFA HL 23 006 Funding Number: RFA HL 23 006 Agency: National Institutes of Health Category: Education, Health Funding Amount: Case Dependent |
| Epidemiologic Research on Emerging Risk Factors and Liver Cancer Susceptibility (R01 Clinical Trial Not Allowed) Apply for PAR 22 083 Funding Number: PAR 22 083 Agency: National Institutes of Health Category: Education, Health Funding Amount: Case Dependent |
| Cancer Tissue Engineering Collaborative: Enabling Biomimetic Tissue-Engineered Technologies for Cancer Research (R01 Clinical Trial Optional) Apply for PAR 22 099 Funding Number: PAR 22 099 Agency: National Institutes of Health Category: Education, Health Funding Amount: $40,000 |
| Emergency Awards: HEAL Initiative: Translational Science Career Enhancement Awards for Early and Mid-career Investigators (K18 Clinical Trials Not Allowed) Apply for PAR 22 058 Funding Number: PAR 22 058 Agency: National Institutes of Health Category: Education, Health Funding Amount: Case Dependent |
| Evaluating the Impact of COVID-19 Pandemic-related Food and Housing Policies and Programs on Health Outcomes in Health Disparity Populations (R01 Clinical Trial Optional) Apply for RFA NR 22 001 Funding Number: RFA NR 22 001 Agency: National Institutes of Health Category: Education, Health Funding Amount: Case Dependent |
| Integrating Mental Health Care into Health Care Systems in Low- and Middle-Income Countries (R01 Clinical Trial Optional) Apply for RFA MH 22 130 Funding Number: RFA MH 22 130 Agency: National Institutes of Health Category: Education, Health Funding Amount: Case Dependent |
| Limited Competition: NIH Neuroscience Doctoral Readiness Program (DR. Program) (R25 Clinical Trial Not Allowed) Apply for RFA NS 22 035 Funding Number: RFA NS 22 035 Agency: National Institutes of Health Category: Education, Health Funding Amount: Case Dependent |
| Data, Evaluation and Coordinating Center for: A Multilevel Approach to Connecting Underrepresented Populations to Clinical Trials (CUSP2CT) (U24 Clinical Trial Not Allowed) Apply for RFA CA 22 014 Funding Number: RFA CA 22 014 Agency: National Institutes of Health Category: Education, Health Funding Amount: $350,000 |
| Investigating Transposable Elements and Mobile DNA as Targets of Integration for Establishing HIV Reservoirs in the Brain (R61/R33 - Clinical Trial Optional) Apply for RFA DA 23 003 Funding Number: RFA DA 23 003 Agency: National Institutes of Health Category: Education, Health Funding Amount: Case Dependent |
| Microbial-based Cancer Imaging and Therapy - Bugs as Drugs (R21 Clinical Trial Not Allowed) Apply for PAR 22 086 Funding Number: PAR 22 086 Agency: National Institutes of Health Category: Education, Health Funding Amount: $200,000 |
| Microbial-based Cancer Imaging and Therapy - Bugs as Drugs (R01 Clinical Trial Not Allowed) Apply for PAR 22 085 Funding Number: PAR 22 085 Agency: National Institutes of Health Category: Education, Health Funding Amount: Case Dependent |
| Administrative Supplements to Support Cancer Disparity Collaborative Research (Clinical Trial Optional) Apply for PAR 22 114 Funding Number: PAR 22 114 Agency: National Institutes of Health Category: Education, Health Funding Amount: Case Dependent |
| Implementing Comprehensive HIV services in Syringe Service Program (SSP) Settings (R34 - Clinical Trial Required) Apply for RFA DA 23 007 Funding Number: RFA DA 23 007 Agency: National Institutes of Health Category: Education, Health Funding Amount: Case Dependent |
Grant application guides and resources
It is always free to apply for government grants. However the process may be very complex depending on the funding opportunity you are applying for. Let us help you!
Apply for Grants
Inside Our Applicants Portal
Access Applicants Portal
- Grants Repository - Access current and historic funding opportunities with ease. Thousands of funding opportunities are published every week. We can help you sort through the database and find the eligible ones to apply for.
- Applicant Video Guides - The grant application process can be challenging to follow. We can help you with intuitive video guides to speed up the process and eliminate errors in submissions.
- Grant Proposal Wizard - We have developed a network of private funding organizations and investors across the United States. We can reach out and submit your proposal to these contacts to maximize your chances of getting the funding you need.
Premium leads for funding administrators, grant writers, and loan issuers
Thousands of people visit our website for their funding needs every day. When a user creates a grant proposal and files for submission, we pass the information on to funding administrators, grant writers, and government loan issuers.
If you manage government grant programs, provide grant writing services, or issue personal or government loans, we can help you reach your audience.
Learn More
Request more information:
Would you like to learn more about this funding opportunity, similar opportunities to "PAR 22 057", eligibility, application service, and/or application tips? Submit an inquiry below:
Don't forget to subscribe to our grant alerts mailing list to receive weekly alerts on new and updated grant funding opportunities like this one in your email.